Since PSAT1, MTB, TP53, and LONP1 were all suggested to be related to CD4+ T cell activation, especially Th cells, we speculate that they have the potential for adjuvant immunotherapy based on CD4+ T cells and improve survival in patients with GC. Here, TP53 is linked to gastric cancer.